The Adult Leukemia program is part of the Hematologic Oncology (Blood Cancers) Treatment Center. Our specialists are highly experienced in treating patients with acute and chronic leukemia, myeloproliferative disorders and myelodysplastic syndromes.
The Adult Leukemia Program provides care for patients with leukemia, such as acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and related bone marrow disorders, including myelodysplasia and myelofibrosis. Our program is one of the most experienced in the nation, with a high volume of consultations, patients cared for, and clinical trials offered. Through our program of clinical research, we apply our ongoing understanding of leukemia to developing therapies that will benefit patients today and in the future.
The Adult Leukemia Program provides comprehensive services for patients with acute leukemia and related disorders. These include:
A highly focused and experienced team of physicians, practitioners and clinical researchers work to provide state-of-the-art compassionate care with an emphasis on cutting-edge clinical research. Physicians work closely with research scientists in a "bench-to-bedside" approach that identifies promising new treatments by rapidly translating laboratory discoveries into the clinical setting.
Richard M. Stone, MD, Program DirectorDaniel J. DeAngelo, MD, PhD, Director, Clinical and Translational ResearchMartha Wadleigh, MD, Clinical Director
Gregory Abel, MDDavid P. Steensma, MDRichard M. Stone, MDMartha Wadleigh, MD
Benjamin Ebert, MD, PhDDavid A. Frank, MD, PhDAndrew Lane, MD, PhDR. Coleman Lindsley, MD, PhDJames Griffin, MD, Chair, Department of Medical OncologyAnthony G. Letai, MD, PhD Ann Mullally, MDDavid Weinstock, MD
Susan Buchanan, PA-C, MHPSarah Cahill, PA-CKatherine Edmonds, ARNPIlene Galinsky, MSN, ANP-CAdriana Penicaud, PA-C
We work closely with our transplant service team when patients require bone marrow/stem cell transplantation.
The clinical research mission of the Adult Leukemia Program is to develop and bring new and better therapies to patients. At any given time, the program offers patients a wide array of opportunities to participate in clinical research studies relating to all stages and types of leukemia and related disorders. Patients have access to trials that originate within Dana-Farber/Brigham and Women's Cancer Center and other Harvard-affiliated institutions, those sponsored by private industry, as well as those that are part of a collaborative effort, such as the Cancer and Leukemia Group B, of which the program is a member.
Physician-researchers within the program are currently involved in a number of exciting avenues of investigation, which include targeted therapies aimed at making cancer treatment more specific and less toxic. These include:
Other innovative offerings include treating adults with acute lymphoblastic leukemia by applying the principles used in successful pediatric treatments of this condition and clinical trials and treatments specialized for older adults.
See current clinical trials for leukemia and myelodysplastic syndromes at Dana-Farber
Leukemia: 617-632-6028 or 617-632-5138, or use this online form to make an appointment.
Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.
Hematologic Malignancies DivisionDana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: